According to sources close to the developments, the price for India may be less than $10 per dosage, making it the lowest in the world.

Pfizer CEO Albert Bourla stated that his business would be able to produce 3 billion doses of its vaccine by the end of 2021, and about 4 billion vaccinations by the end of 2022.

Pfizer CEO Albert Bourla stated that the firm is in the final stages of striking an arrangement with the Indian government to provide its Covid-19 vaccines.

Bourla, according to news outlets, stated, “We are negotiating with the Indian administration.” We are nearing the end of the process of finalising the agreement.” Bourla was presenting at the USA-India Chamber of Commerce’s BioPharma & Healthcare Summit (USAIC). “I expect to finalise an arrangement with the government very soon,” he continued.

Sources close to the developments have previously stated that the pricing for India might be less than $10 per dose, the lowest in the world thus far. Pfizer has also said that during the pandemic, it will exclusively sell its vaccine to the Government of India and not to any other entity. Estimates suggest that between July and October of current year, about 50 million doses might be delivered to India.

The firm, on the other hand, has requested indemnification in the purchase agreement, which will shield it from legal lawsuits if the vaccinations have any bad effects when delivered. Its officials interact with the country’s authorities on a regular basis and recently delivered detailed data from worldwide trials.

Pfizer, according to Bourla, will be able to produce 3 billion doses of its vaccine by the end of 2021, and about 4 billion vaccinations by the end of 2022.

Pfizer-Covid BioNTech’s vaccine BNT162b2, based on mRNA technology, has demonstrated 95% effectiveness against Covid and nearly 100% efficacy against severe illness. In the United States, the vaccination is also authorised for teenagers above the age of 12.

Bourla stated that the business has special measures in place to satisfy vaccination demand in low- and middle-income nations like as India.

These nations are expected to get 2 billion doses of the vaccine, with around 1 billion given this year.

Pfizer has signed a contract with the US government for 500 million pills. The US government may provide these dosages to low- and middle-income countries.